Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Aspirin suppresses PGE2 and activates AMP kinase to inhibit melanoma cell motility, pigmentation and selective tumor growth in vivo.

Kumar D, Rahman H, Tyagi E, Liu T, Li C, Lu R, Lum D, Holmen SL, Maschek JA, Cox JE, VanBrocklin MW, Grossman D.

Cancer Prev Res (Phila). 2018 Jul 18. pii: canprevres.0087.2018. doi: 10.1158/1940-6207.CAPR-18-0087. [Epub ahead of print]

PMID:
30021726
2.

Mutant IDH1 Promotes Glioma Formation In Vivo.

Philip B, Yu DX, Silvis MR, Shin CH, Robinson JP, Robinson GL, Welker AE, Angel SN, Tripp SR, Sonnen JA, VanBrocklin MW, Gibbons RJ, Looper RE, Colman H, Holmen SL.

Cell Rep. 2018 May 1;23(5):1553-1564. doi: 10.1016/j.celrep.2018.03.133.

3.

A Nonsynonymous Variant in the GOLM1 Gene in Cutaneous Malignant Melanoma.

Teerlink CC, Huff C, Stevens J, Yu Y, Holmen SL, Silvis MR, Trombetti K, Zhao H, Grossman D, Farnham JM, Wen J, Facelli JC, Thomas A, Babst M, Florell SR, Meyer L, Zone JJ, Leachman S, Cannon-Albright LA.

J Natl Cancer Inst. 2018 Apr 11. doi: 10.1093/jnci/djy058. [Epub ahead of print]

PMID:
29659923
4.

Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma.

Yu Y, Schleich K, Yue B, Ji S, Lohneis P, Kemper K, Silvis MR, Qutob N, van Rooijen E, Werner-Klein M, Li L, Dhawan D, Meierjohann S, Reimann M, Elkahloun A, Treitschke S, Dörken B, Speck C, Mallette FA, Zon LI, Holmen SL, Peeper DS, Samuels Y, Schmitt CA, Lee S.

Cancer Cell. 2018 Apr 9;33(4):785. doi: 10.1016/j.ccell.2018.03.009. No abstract available.

PMID:
29634951
5.

Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma.

Yu Y, Schleich K, Yue B, Ji S, Lohneis P, Kemper K, Silvis MR, Qutob N, van Rooijen E, Werner-Klein M, Li L, Dhawan D, Meierjohann S, Reimann M, Elkahloun A, Treitschke S, Dörken B, Speck C, Mallette FA, Zon LI, Holmen SL, Peeper DS, Samuels Y, Schmitt CA, Lee S.

Cancer Cell. 2018 Feb 12;33(2):322-336.e8. doi: 10.1016/j.ccell.2018.01.002. Erratum in: Cancer Cell. 2018 Apr 9;33(4):785.

6.

Resistance mechanisms to genetic suppression of mutant NRAS in melanoma.

Robinson JP, Rebecca VW, Kircher DA, Silvis MR, Smalley I, Gibney GT, Lastwika KJ, Chen G, Davies MA, Grossman D, Smalley KSM, Holmen SL, VanBrocklin MW.

Melanoma Res. 2017 Dec;27(6):545-557. doi: 10.1097/CMR.0000000000000403.

PMID:
29076949
7.

Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma.

Hong A, Moriceau G, Sun L, Lomeli S, Piva M, Damoiseaux R, Holmen SL, Sharpless NE, Hugo W, Lo RS.

Cancer Discov. 2018 Jan;8(1):74-93. doi: 10.1158/2159-8290.CD-17-0682. Epub 2017 Sep 18.

PMID:
28923912
8.

Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis.

Gardner LJ, Ward M, Andtbacka RHI, Boucher KM, Bowen GM, Bowles TL, Cohen AL, Grossmann K, Hitchcock YJ, Holmen SL, Hyngstrom J, Khong H, McMahon M, Monroe MM, Ross CB, Suneja G, Wada D, Grossman D.

Melanoma Res. 2017 Oct;27(5):477-484. doi: 10.1097/CMR.0000000000000382.

PMID:
28800031
9.

In vitro visualization and characterization of wild type and mutant IDH homo- and heterodimers using Bimolecular Fluorescence Complementation.

Robinson GL, Philip B, Guthrie MR, Cox JE, Robinson JP, VanBrocklin MW, Holmen SL.

Cancer Res Front. 2016 May;2(2):311-329. doi: 10.17980/2016.311. Epub 2016 Jul 9.

10.

HBEGF promotes gliomagenesis in the context of Ink4a/Arf and Pten loss.

Shin CH, Robinson JP, Sonnen JA, Welker AE, Yu DX, VanBrocklin MW, Holmen SL.

Oncogene. 2017 Aug 10;36(32):4610-4618. doi: 10.1038/onc.2017.83. Epub 2017 Apr 3.

11.

Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma.

Yang H, Kircher DA, Kim KH, Grossmann AH, VanBrocklin MW, Holmen SL, Robinson JP.

Oncogene. 2017 Jul 6;36(27):3842-3851. doi: 10.1038/onc.2016.526. Epub 2017 Mar 6.

12.

Melanoma central nervous system metastases: current approaches, challenges, and opportunities.

Cohen JV, Tawbi H, Margolin KA, Amravadi R, Bosenberg M, Brastianos PK, Chiang VL, de Groot J, Glitza IC, Herlyn M, Holmen SL, Jilaveanu LB, Lassman A, Moschos S, Postow MA, Thomas R, Tsiouris JA, Wen P, White RM, Turnham T, Davies MA, Kluger HM.

Pigment Cell Melanoma Res. 2016 Nov;29(6):627-642. doi: 10.1111/pcmr.12538. Epub 2016 Oct 22. Review.

13.

Melanoma Brain Metastasis: Mechanisms, Models, and Medicine.

Kircher DA, Silvis MR, Cho JH, Holmen SL.

Int J Mol Sci. 2016 Sep 2;17(9). pii: E1468. doi: 10.3390/ijms17091468. Review.

14.

A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma.

Ray A, Williams MA, Meek SM, Bowen RC, Grossmann KF, Andtbacka RH, Bowles TL, Hyngstrom JR, Leachman SA, Grossman D, Bowen GM, Holmen SL, VanBrocklin MW, Suneja G, Khong HT.

Oncotarget. 2016 Sep 27;7(39):64390-64399. doi: 10.18632/oncotarget.10453.

15.

Melanoma metastases caught in the AKT.

Kircher DA, Arave RA, Cho JH, Holmen SL.

Mol Cell Oncol. 2016 Feb 18;3(2):e1128516. doi: 10.1080/23723556.2015.1128516. eCollection 2016 Mar.

16.

AKT1 Activation Promotes Development of Melanoma Metastases.

Cho JH, Robinson JP, Arave RA, Burnett WJ, Kircher DA, Chen G, Davies MA, Grossmann AH, VanBrocklin MW, McMahon M, Holmen SL.

Cell Rep. 2015 Nov 3;13(5):898-905. doi: 10.1016/j.celrep.2015.09.057. Epub 2015 Oct 22.

17.

The BRAF kinase domain promotes the development of gliomas in vivo.

Shin CH, Grossmann AH, Holmen SL, Robinson JP.

Genes Cancer. 2015 Jan;6(1-2):9-18.

18.

Gα13 mediates human cytomegalovirus-encoded chemokine receptor US28-induced cell death in melanoma.

Joshi S, Wels C, Beham-Schmid C, Fukunaga-Kalabis M, Holmen SL, Otte M, Herlyn M, Waldhoer M, Schaider H.

Int J Cancer. 2015 Sep 15;137(6):1503-8. doi: 10.1002/ijc.29506. Epub 2015 Mar 16.

19.

Akt signaling accelerates tumor recurrence following ras inhibition in the context of ink4a/arf loss.

Robinson GL, Robinson JP, Lastwika KJ, Holmen SL, Vanbrocklin MW.

Genes Cancer. 2013 Nov;4(11-12):476-85. doi: 10.1177/1947601913513268.

20.

IDH1 and IDH2 mutations in gliomas.

Cohen AL, Holmen SL, Colman H.

Curr Neurol Neurosci Rep. 2013 May;13(5):345. doi: 10.1007/s11910-013-0345-4. Review.

21.

Familial melanoma-associated mutations in p16 uncouple its tumor-suppressor functions.

Jenkins NC, Jung J, Liu T, Wilde M, Holmen SL, Grossman D.

J Invest Dermatol. 2013 Apr;133(4):1043-51. doi: 10.1038/jid.2012.401. Epub 2012 Nov 29.

22.

Ink4a/Arf loss promotes tumor recurrence following Ras inhibition.

Vanbrocklin MW, Robinson JP, Lastwika KJ, McKinney AJ, Gach HM, Holmen SL.

Neuro Oncol. 2012 Jan;14(1):34-42. doi: 10.1093/neuonc/nor184. Epub 2011 Oct 20.

23.

Akt signaling is required for glioblastoma maintenance in vivo.

Robinson JP, Vanbrocklin MW, McKinney AJ, Gach HM, Holmen SL.

Am J Cancer Res. 2011;1(2):155-167.

25.

Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo.

Robinson JP, Vanbrocklin MW, Lastwika KJ, McKinney AJ, Brandner S, Holmen SL.

Oncogene. 2011 Mar 17;30(11):1341-50. doi: 10.1038/onc.2010.513. Epub 2010 Nov 8.

26.

Targeted delivery of NRASQ61R and Cre-recombinase to post-natal melanocytes induces melanoma in Ink4a/Arflox/lox mice.

VanBrocklin MW, Robinson JP, Lastwika KJ, Khoury JD, Holmen SL.

Pigment Cell Melanoma Res. 2010 Aug;23(4):531-41. doi: 10.1111/j.1755-148X.2010.00717.x. Epub 2010 Apr 23.

27.

Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation.

Robinson JP, VanBrocklin MW, Guilbeault AR, Signorelli DL, Brandner S, Holmen SL.

Oncogene. 2010 Jan 21;29(3):335-44. doi: 10.1038/onc.2009.333. Epub 2009 Oct 26.

28.

Met amplification and tumor progression in Cdkn2a-deficient melanocytes.

Vanbrocklin MW, Robinson JP, Whitwam T, Guilbeault AR, Koeman J, Swiatek PJ, Vande Woude GF, Khoury JD, Holmen SL.

Pigment Cell Melanoma Res. 2009 Aug;22(4):454-60. doi: 10.1111/j.1755-148X.2009.00576.x. Epub 2009 Apr 29.

29.

Mitogen-activated protein kinase inhibition induces translocation of Bmf to promote apoptosis in melanoma.

VanBrocklin MW, Verhaegen M, Soengas MS, Holmen SL.

Cancer Res. 2009 Mar 1;69(5):1985-94. doi: 10.1158/0008-5472.CAN-08-3934. Epub 2009 Feb 24.

30.

Inhibition of Marek's disease virus replication by retroviral vector-based RNA interference.

Chen M, Payne WS, Hunt H, Zhang H, Holmen SL, Dodgson JB.

Virology. 2008 Aug 1;377(2):265-72. doi: 10.1016/j.virol.2008.03.019.

31.

Inhibition of avian leukosis virus replication by vector-based RNA interference.

Chen M, Granger AJ, Vanbrocklin MW, Payne WS, Hunt H, Zhang H, Dodgson JB, Holmen SL.

Virology. 2007 Sep 1;365(2):464-72. Epub 2007 May 9.

32.

Differential oncogenic potential of activated RAS isoforms in melanocytes.

Whitwam T, Vanbrocklin MW, Russo ME, Haak PT, Bilgili D, Resau JH, Koo HM, Holmen SL.

Oncogene. 2007 Jul 5;26(31):4563-70. Epub 2007 Feb 5.

PMID:
17297468
33.

APC inhibits ERK pathway activation and cellular proliferation induced by RAS.

Park KS, Jeon SH, Kim SE, Bahk YY, Holmen SL, Williams BO, Chung KC, Surh YJ, Choi KY.

J Cell Sci. 2006 Mar 1;119(Pt 5):819-27. Epub 2006 Feb 14.

34.

Essential role for Ras signaling in glioblastoma maintenance.

Holmen SL, Williams BO.

Cancer Res. 2005 Sep 15;65(18):8250-5.

35.
36.

Essential role of beta-catenin in postnatal bone acquisition.

Holmen SL, Zylstra CR, Mukherjee A, Sigler RE, Faugere MC, Bouxsein ML, Deng L, Clemens TL, Williams BO.

J Biol Chem. 2005 Jun 3;280(22):21162-8. Epub 2005 Mar 31.

37.

Wnt-independent activation of beta-catenin mediated by a Dkk1-Fz5 fusion protein.

Holmen SL, Robertson SA, Zylstra CR, Williams BO.

Biochem Biophys Res Commun. 2005 Mar 11;328(2):533-9.

PMID:
15694380
38.

Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6.

Holmen SL, Giambernardi TA, Zylstra CR, Buckner-Berghuis BD, Resau JH, Hess JF, Glatt V, Bouxsein ML, Ai M, Warman ML, Williams BO.

J Bone Miner Res. 2004 Dec;19(12):2033-40. Epub 2004 Sep 13.

39.

Delivery of short hairpin RNA sequences by using a replication-competent avian retroviral vector.

Bromberg-White JL, Webb CP, Patacsil VS, Miranti CK, Williams BO, Holmen SL.

J Virol. 2004 May;78(9):4914-6.

40.

A novel set of Wnt-Frizzled fusion proteins identifies receptor components that activate beta -catenin-dependent signaling.

Holmen SL, Salic A, Zylstra CR, Kirschner MW, Williams BO.

J Biol Chem. 2002 Sep 20;277(38):34727-35. Epub 2002 Jul 16.

42.
43.

Soluble forms of the subgroup A avian leukosis virus [ALV(A)] receptor Tva significantly inhibit ALV(A) infection in vitro and in vivo.

Holmen SL, Salter DW, Payne WS, Dodgson JB, Hughes SH, Federspiel MJ.

J Virol. 1999 Dec;73(12):10051-60.

44.

Efficient lipid-mediated transfection of DNA into primary rat hepatocytes.

Holmen SL, Vanbrocklin MW, Eversole RR, Stapleton SR, Ginsberg LC.

In Vitro Cell Dev Biol Anim. 1995 May;31(5):347-51.

PMID:
7633672

Supplemental Content

Loading ...
Support Center